Head-to-head evidence
ecnoglutide vs TE-8105
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ecnoglutide
Marketed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 664 adults with overweight or obesity. Ecnoglutide 2.4 mg produced a significantly greater reduction in body weight than placebo at week 40, -13.2% vs +0.1%, p<0.0001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07553299 (registry estimate)
TE-8105
Developed by Immunwork
NCT06471530 · Phase 1/2 · completed
This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ecnoglutide's landscape · TE-8105's landscape